Kornimate/medical-research-clean huggingface dataset:
the effects of pentoxifylline on pai-1 in an obese population

Conditions: Obesity

Summary: pai-1 is elevated in obese individuals. tnf-alpha, an inflammatory mediator is believed to play a role in obesity mediated elevations in pai-1 levels. tnf-alpha blockade with antibodies and the drug pentoxifylline have been shown to lower pai-1 levels in animal models. this study tests the hypothesis that pentoxifylline will lower pai-1 levels in human subjects.

obese individuals with elevated pai-1 levels (greater than 10 ng/ml) are randomized to pentoxifylline 400mg, three times a day (tid) or placebo for 8 weeks. pai-1, tnf-a and high sensitivity c-reactive protein are measured at week 0, 4 and 8.

Eligibility criteria:
inclusions: 1. a body mass index of ≥ 30.0 2. age 21 or older 3. few or no medical problems 4. pai-1 level ≥ 10 ng/dl exclusions: 1. cigarette use 2. present use of angiotensin converting enzyme (ace) inhibitors 3. recent cerebral and/or retinal hemorrhage 4. intolerance to pentoxifylline or methylxanthines such as caffeine, theophylline, and theobromine 5. presently on warfarin therapy 6. pregnancy or breast-feeding 7. recent surgery 8. recent diagnosis/treatment for peptic ulcer

Keywords: plasma pai-1 level at 0, 4, 8 weeks plasma hscrp level at 0, 4, 8 weeks plasma tnf-a level at 0, 4, 8 weeks
a study of abciximab and reteplase when administered prior to catherization after a myocardial infarction (finesse)

Conditions: Myocardial Infarction

Summary: the purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention.

the purpose of this medical research study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention. this medical research study will also help determine if the combination of abciximab and reduced dose reteplase will decrease the risk of death, and reduce complications of a heart attack at 90 days compared to abciximab alone which is a standard treatment. patients will receive either abciximab and reteplease or abciximab alone. safety evaluations will be performed at specified intervals throughout the study and will consist of laboratory tests, vital signs (such as blood pressure), physical examinations and the occurrence and severity of adverse events as well as other study specific procedures. patients will receive either abciximab and reteplease or abciximab and placebo into a vein in their arm for up to 12 hours.

Eligibility criteria:
inclusion criteria: * patients who have prolonged, continuous (lasting at least 20 minutes) signs and symptoms of a heart attack not eliminated with nitrates and onset within 6 hours of randomization,and confirmation by electrocardiogram exclusion criteria: * low risk clinical presentation * patients who will not be undergoing a catherization within 4 hours of the qualifying electrocardiogram

Keywords: myocardial infarction percutaneous coronary intervention abciximab reteplase safety and efficacy
tmtp1-icg mapping in colposcopy-directed biopsy

Conditions: Cervical Intraepithelial Neoplasia

Summary: investigators aimed to determine the validity of the novel tumor targeted fluorescent tmtp1-icg to increased accuracy of colposcopy-directed biopsy.


Eligibility criteria:
inclusion criteria: * suspicious of cervical disease required a colposcopy-directed biopsy. * subjects must sign an informed consent indicating awareness of the investigational nature of this study. exclusion criteria: * breast-feeding or pregnant. * ongoing participation in another clinical trial with an investigational drug with 3 months. * own allergy towards icg and/or alcohol. * diagnosis of bacterial vaginosis, fungal vaginitis, sexually transmitted diseases. * patients with cardiac dysfunction or hepatic insufficiency or renal insufficiency.
neuromedulatory effect of transcranial direct current electrical stimulation in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: this is a double blinded randomized clinical trial to study the neuromodulatory effect of tdcs in patients with cts, the study subject will be randomly into two groups; active and sham group , the active group will receive five sessions of active tdcs over the m1 while the sham group will receive sham tdcs in which the device will be turned off after 30 seconds. the patient will be assessed by vas score, boston carpal tunnel questionnaire , central sensetization inventory , pressure pain threshold, sensory and pain threshold for electerical stimulation before , after the end of the sessions and 4 weeks later.

the study will be carried out on patients attending the physical medicine, rheumatology and rehabilitation outpatient clinic in suez canal university hospital, ismailia, egypt and diagnosed with cts according to clinical examination and to the american association of neuromuscular and electrodiagnostic medicine (aanem) practice recommendations for cts. study subjects will be divided into two groups: group (1): (active group) will include 42 patients with cts and will receive anodal tdcs of m1 for 20 minutes, at 2 ma for 5 sessions and less than 72 hrs. may be allowed between experimental sessions for each participant to avoid any interference. group (2): (sham group) will include 42 patients with cts and will receive sham tdcs m1 (the set will be turned off after 30 seconds) for 20 minutes, at 2 ma for 5 sessions. the study sample will be collected from all patients with cts attending to the physical medicine, rheumatology and rehabilitation outpatient clinic in suez canal university hospital fulfilling the eligibility criteria, will be eligible to join the study (either referred for electrophysiological study or presented to the clinic for primary assessment). to make sure that no bias should enter the assessment of the results, neither the patient nor the clinicians will be aware whether active tdcs will be applicated to a particular case. to ensure this result, two symbols (square and triangle) will be applicated to the physiotherapy sheet and only the physiotherapist knew the key for each symbol. the triangle may represent the cases of cts for active tdcs and the square may represent the sham group or vice versa. at the end of the study the two groups will be revealed in order to analyze the results according to proper statistical measures.

Eligibility criteria:
inclusion criteria: patient diagnosed as cts by history, clinical examination and ncs for more than 3 months. both genders. adult of aged 18 years and above. able to understand the informed consent. exclusion criteria: patients with diabetes mellitus, collagen disorders, thyroid disease, peripheral neuropathy, traumatic nerve injury, cervical radiculopathy, fibromyalgia. pregnancy. malignant. patients with any clinically significant or unstable medical or psychiatric disorder.
ultrasound as a diagnostic tool for rotator cuff tears

Conditions: Rotator Cuff Tear

Summary: after comparing ultrasound study of rotator cuff injuries that have been evaluated both in the community and in a hospital-based ultrasound service with actual surgical findings, it is expected that specialist performed imaging and evaluation will be most accurate and that those performed in the community will be not accurate enough.


Eligibility criteria:
inclusion criteria: * symptomatic rotator cuff tears indication for rotator cuff repair exclusion criteria: * severe arm movement limitations

Keywords: accuracy of diagnostic ultrasound based in community or as part of a specialist hospital-based service
machine learning-based surgical guidance system for robot-assisted rectal surgery

Conditions: Rectum Cancer

Summary: the aim of the study is to evaluate the technical feasibility and applicability of a surgical assistance system based on image recognition algorithms in a first-in-human pilot study. in addition, this study will provide preliminary data on the oncological outcome of the assistance system.


Eligibility criteria:
inclusion criteria: * patients with rectal cancer scheduled for robot-assisted rectal resection * intact preoperative urogenital/rectal function * full capability of consent exclusion criteria: * previous/second malignant disease \<5 years before diagnosis of rectal cancer * previous abdominal surgery, except for appendectomy, cholecystectomy or cesarean section

Keywords: robotic surgery total mesorectal excision
motion analysis of emp knee versus posterior stabilized knee arthroplasty for osteoarthritis

Conditions: Arthropathy of Knee Joint

Summary: the purpose of the current study is to analyze and compare the lower-limb joint motions and muscle activation patterns during activities of daily living as well as self reported health related functional outcomes for patients with osteoarthritis of the knee undergoing one of two types of knee replacements: the evolution medial pivot knee (wright medical) or the triathlon posterior stabilized (ps) knee (stryker orthopaedics).

inclusion: 40 patients between the ages of 50 and 75 yrs undergoing unilateral total knee replacement for non-inflammatory degenerative osteoarthritis will participate, as well as 10 control participants will be recruited from the general population for the present study matching to experimental groups for age, gender and bmi. patients who do not meet any exclusion criteria. exclusion: potential participants for the control group will be asked if they have had degenerative osteoarthritis of lower-limb joints (hip, knee and ankle) and if they have they will be excluded. exclusion for patient group 1. patients suffering from any other lower-limb joint disorders other than the one for which total knee arthroplasty. 2. patients with any other joint replacement in the ipsilateral and contralateral limb. 3. patients with evidence of active infection. 4. patients with neurologic or musculoskeletal disease that may adversely affect gait, weight-bearing or quadriceps function. 5. patients with neuropathic joints. 6. patients requiring structural bone grafts. 7. patients with a documented allergy to cobalt chromium molybdenum. 8. patient with a bmi larger than 30 kg/m2.

Eligibility criteria:
inclusion criteria: * 40 patients between the ages of 50 and 75 yrs undergoing unilateral total knee replacement for non-inflammatory degenerative osteoarthritis will participate, as well as 10 control participants will be recruited from the general population for the present study matching to experimental groups for age, gender and bmi.patients who do not meet any exclusion criteria. exclusion criteria: * potential participants for the control group will be asked if they have had degenerative osteoarthritis of lower-limb joints (hip, knee and ankle) and if they have they will be excluded. exclusion for patient group 1. patients suffering from any other lower-limb joint disorders other than the one for which total knee arthroplasty. 2. patients with any other joint replacement in the ipsilateral and contralateral limb. 3. patients with evidence of active infection. 4. patients with neurologic or musculoskeletal disease that may adversely affect gait, weight-bearing or quadriceps function. 5. patients with neuropathic joints. 6. patients requiring structural bone grafts. 7. patients with a documented allergy to cobalt chromium molybdenum. 8. patient with a bmi larger than 30 kg/m2.

Keywords: knee replacement motion analysis
research of double-positive circulating cells (tumor marker / cd45+) in several types of metastatic cancers

Conditions: Urothelial Carcinoma; Renal Cancer; Prostate Adenocarcinoma; Adenocarcinoma of Endometrium; Cutaneous Melanoma; Soft Tissue Sarcoma (STS); Nonseminomatous Germ Cell Tumor; Seminomatous Germ Cell Tumor; Upper Aerodigestive Tract Carcinoma; Cervical Carcinoma

Summary: a prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the iuct-o or possibly in other institutions. eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect dp-circulating cells by 2 different methods of analysis. each patient will participate in the study for one day. the methods of analysis will be: flow cytometry for all patients and either parsotix® or cellsearch® depending on the type of cancer. 450 patients will be enrolled in total.


Eligibility criteria:
inclusion criteria: * 1. patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors * 2. metastatic disease for which the treatment (whatever the line) has not been initiated yet * 3. age ≥ 18 years * 4. patient affiliated to a french social security scheme * 5. patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study. exclusion criteria: * 1. patient with localized disease. * 2. pregnant or breast-feeding women. * 3. any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol. * 4. patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Keywords: metastatic cancers double positive circulating cells liquid biopsy
glycemic control in diabetic hospitalized patients

Conditions: Diabetes; Diabetes Mellitus

Summary: with the advanced management of diabetes and new innovative anti-hyperglycemic therapy hyperglycemia remains a culprit factor affecting the outcome of patients admitted to the hospital in general wards. efforts from health care providers to assess and control blood sugar by a simplified method such as certified point of care hand-sized glucometers is the fruitful protocol if the results near the target that is endorsed by well-known diabetes societies. in non-critically patients the premeal blood sugar ≤140 mg /dl and ≤ 180 mg /dl after a meal. the unstable economy and political crises with the pandemic of covid-19 making us use a glucometer to monitor and control the fluctuation of blood sugar in order to decrease the burden on the patients and health care providers in the form of a stay in the hospital and minimize wasting laboratory resources.


Eligibility criteria:
inclusion criteria: * admitted to the hospital exclusion criteria: * none

Keywords: diabetes mellitus hyperglycemia glycemic control inpatient
evaluation of the benefits of sublingual ait (practis)

Conditions: Allergic Rhinitis

Summary: the objective of the study was to evaluate in routine practice the benefits of sublingual allergen immunotherapy (slit) for allergic patients with allergic rhinitis (ar), with or without asthma, according to various methods of use (treatment regimen: formulation type, dose, duration, initiation) and type of allergen (grass pollen, tree pollen, herbaceous pollen, house dust mites, animal dander, moulds and poly-reactive types).

the treatment considered was any slit (tablet or liquid forms) accepted by the patient and the parent(s) in the case of minor patients. the treatment was taken as prescribed by the observing physician. the expected benefits for patients after approximately 6 and 12 months after initiation of slit included: * decreased intensity of symptoms * decreased discomfort * decreased consumption of symptomatic treatments or associated treatments (especially in asthmatic patients) * improved quality of life * reduced absenteeism from school or work * beneficial impact on leisure activities.

Eligibility criteria:
inclusion criteria: * patients aged 5 years or older * patients with a respiratory allergy with significant clinical symptoms and whose diagnosis was confirmed by a positive skin prick-test and/or the presence of specific ige antibodies to one or more allergens implicated in the symptoms * patients eligible for ait (patients who had been treated with ait in the 3 years prior to the inclusion visit could be included if starting a new form and/or type of ait) * patients previously treated with a pharmacological ar treatment in the month before the inclusion visit or during the previous pollen season, and requiring the initiation of ait * patients (and/or their parents or legal representatives as appropriate) agreeing to take part in the study after having been informed orally and in writing by the observing physician. exclusion criteria: * patient with a hypersensitivity (allergy) to any of the excipients in the selected ait * patients taking beta-blockers (including local treatments, e.g. eye drops) * if asthmatic patient: * patients with uncontrolled (unstable) or severe asthma (in adults this was defined as daily symptoms and fev1 \<70% of the theoretical value after appropriate drug treatment, and in children and adolescents by fev1 \<80% of the theoretical value after appropriate drug treatment) * patients who have had a severe asthma exacerbation in the last three months * asthmatic patient with unresolved acute infection of the airways.

Keywords: slit treatment, patient adherence/satisfaction, pbi
comparison of pitavastatin with atorvastatin in increasing high density lipoprotein - cholesterol (hdl-c) and adiponectin in patients with dyslipidemia and coronary artery disease (cad)

Conditions: Hypercholesterolemia; Coronary Artery Disease

Summary: the purpose of this study is to compare the effects of pitavastatin and atorvastatin on adiponectin percentage change in patients with hypercholesteremia comorbid stable cad.

the efficiency of lipid lowering therapy was already proven by the clinical trials of statins. according to these results, the target value of ldl-c is recommended under 100mg/dl in the japan atherosclerosis society guidelines. however, the efficiency of intensive therapy to lower ldl-c more than 100mg/dl has not been proven yet.

Eligibility criteria:
inclusion criteria: * patients with dyslipidemia as defined by any of the parameters: * hdl-c \< 50 mg/dl * ldl-c ≥ 140 mg/dl * ldl-c ≥ 100 mg/dl and cholesterol-lowering treatment is necessary in accordance with the investigator's judgement * patients who passed three months or more after acute myocardial infarction * patients who passed one month or more after unstable angina * patients who passed one month or more after pci * patients with written consent by their own volition after being provided sufficient explanation for the participation into this clinical trial exclusion criteria: * patients with any allergy to pitavastatin or atorvastatin * patients with familial hypercholesterolemia * patients receiving pitavastatin * patients with severe hypertension * patients with renal disorders or undergoing dialysis * patients with hepatobiliary disorders * patients with hepatobiliary disorders * patients with family history of hypothyroidism or muscular dystrophy * patients with history of drug-induced hepatic disorder * drug abuser or dipsomaniac * patients with cardiogenic shock. * patients who hopes for pregnancy during this study * contraindications, relative contraindications, absolute contraindications for coadministration and relative contraindications for coadministration for pitavastatin or atorvastatin * patients who are ineligible in the opinion of the investigator

Keywords: pitavastatin atorvastatin cad hdl-c adiponectin
a phase ii study of icotinib in treating patients with advanced nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: this is a phase 2 study to evaluate the efficacy of single-agent icotinib in patients with advanced nasopharyngeal carcinoma.

this phase 2 study is aimed to evaluate the efficacy of single-agent icotinib in patients with pretreated, advanced nasopharyngeal carcinoma. the primary endpoint is disease control rate (dcr).

Eligibility criteria:
inclusion criteria: * histologically confirmed advanced npc * patients must be platinum-resistant defined as recurrence or progression of disease \<6 months since previous treatment with a platinum based treatment regimen. * measurable disease per recist * adequate organ and marrow function * capable of understanding and complying with the protocol, and written informed consent exclusion criteria: * prior treatment with gefitinib, erlotinib, or other drugs that target egfr * patients must not be receiving any other investigational agents * other serious illness or medical condition including unstable cardiac disease requiring treatment, history of significant neurologic or psychiatric disorders (including psychotic disorders, dementia, or seizures), or active uncontrolled infection * women who are pregnant or breast-feeding
immunogenicity & safety study of a vaccine against meningitis in infants (2,4,6 months) after a hepatitis b birth dose.

Conditions: Diphtheria; Hepatitis B; Haemophilus Influenzae Type b; Whole Cell Pertussis; Tetanus

Summary: the purpose of the study is to demonstrate consistent results in 3 production lots of hib-menac vaccine when extemporaneously mixed with tritanrix™-hepb and administered as a single injection, with respect to immunogenicity, safety and reactogenicity. tritanrix™-hepb/hiberix™ given alone and wyeth lederle's meningococcal c conjugate vaccine (meningitec™), given concomitantly with tritanrix™-hepb/hiberix™ will be used as benchmark vaccines for all antigens except for mena. the immunogenicity of mena will also be evaluated.

randomized study with five groups to receive one of the following vaccination regimens after a birth dose of hepatitis b vaccine: one of the 3 lots of gsk biologicals' hib-menac mixed with gsk biologicals' tritanrix™-hbv (3 different groups) gsk biologicals' tritanrix™-hbv/hiberix™ gsk biologicals' tritanrix™-hbv/hiberix™ +meningitec™

Eligibility criteria:
inclusion criteria: • healthy infants 56-83 days of age, written informed consent obtained from the parents, born after a gestation period of 36 to 42 weeks and received a birth dose of hepatitis b vaccine within the first 72 hours of life. exclusion criteria: * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history \& physical examination. * planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of study vaccine, or planned administration during the study period with the exception of oral polio vaccine (opv). * use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * chronic administration (\>14 days) of immunosuppressants or other immune-modifying drugs since birth. * bacille calmette-guérin (bcg) vaccine received after the first 2 weeks of life. * previous vaccination against diphtheria, tetanus, pertussis, haemophilus influenzae type b, and/or meningococcal disease.